




Q2 2025 Financial Results



Total Revenues

\$3.6B

Adjusted EBITDA*

\$1.1B

Free Cash Flow*
Excluding Transaction-Related Costs

\$241M

Adjusted EPS*

\$0.62



"We delivered a strong second quarter and continued to make meaningful progress against our key 2025 strategic priorities. Our results reflect the strength and resilience of our diversified global business, and our late-stage pipeline continues to advance with encouraging momentum. We remain focused on driving commercial execution, investing in strategic accretive in-market business development opportunities and positioning Viatris for sustainable growth in 2026 and beyond."

– Scott A. Smith
Chief Executive Officer

Delivering on Our 2025 Strategic Priorities

- ... Drive strong commercial execution
- ... Advance our pipeline
- ... Prioritize capital return with focus on share repurchases
- ... Target accretive regional business development
- ... Complete remediation for Indore facility and request reinspection
- ... Conduct enterprise-wide strategic review

Execution

- Q2 operational performance above expectations, with 3% total revenue growth ex Indore⁽¹⁾
- Positive results from five Phase 3 data readouts
- Selatogrel and cenerimod enrollment on track
- Received approval for sotagliflozin in UAE, marking our first approval
- Returned >\$630M of capital to shareholders YTD, including \$350M share repurchases and ~\$280M dividends paid
- Indore facility remediation nearly complete and in August will request an FDA meeting to discuss remediation progress and reinspection
- Strong progress on enterprise-wide strategic review and plan to provide update on Q3 2025 call

* Non-GAAP Financial Measure. For more information about Non-GAAP financial measures and reconciliations to the closest U.S. GAAP financial measure, as well as risks related to forward-looking statements, please read our [Second Quarter 2025 Financial Results press release](#) on our website.

⁽¹⁾ Divestiture-adjusted operational change ex Indore based on Q2 2025 total revenues as compared to Q2 2024 total revenues adj ex divestitures further adjusted for the negative impact related to Indore of ~\$160M.

© 2025 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris Company.



[Viatris.com](#)



[LinkedIn](#)



[@ViatrisInc](#)



[@ViatrisInc](#)



[YouTube](#)



[Listen Well Podcast](#)